A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children

for the Pediatric Emergency Care Applied Research Network (PECARN)

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises.Wehypothesized that intravenousmagnesiumwould shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sb0 thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcomewaslengthof stay inhours fromthetimeof firststudydruginfusion,comparedusing a Van Elteren test. Secondary outcomes included opioid use and HRQL. Of 208 children enrolled, 204 received the study drug (101 magnesium, 103 placebo). Between-group demographics and prerandomization treatment were similar. The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours formagnesiumvs 47.0 (24.0-99.0) hours for placebo (P =.24). Magnesium patients received 1.46 mg/kg morphine equivalents vs 1.28 mg/kg for placebo (P =.12). Changes in HRQL before discharge and 1 week after discharge were similar (P >.05 for all comparisons). The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis.

Original languageEnglish (US)
Pages (from-to)1651-1657
Number of pages7
JournalBlood
Volume126
Issue number14
DOIs
StatePublished - Oct 1 2015

Fingerprint

Magnesium
Randomized Controlled Trials
Pain
Placebos
Quality of Life
Opioid Analgesics
Length of Stay
Pediatrics
Health
Sickle Hemoglobin
Hospitalized Child
Thalassemia
Emergency Medical Services
Vasodilator Agents
Morphine
Hospitalization
Anti-Inflammatory Agents
Demography
Therapeutics
Research

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

for the Pediatric Emergency Care Applied Research Network (PECARN). / A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. In: Blood. 2015 ; Vol. 126, No. 14. pp. 1651-1657.
@article{d09db597f352476a9c7899719d1de93c,
title = "A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children",
abstract = "Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises.Wehypothesized that intravenousmagnesiumwould shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sb0 thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcomewaslengthof stay inhours fromthetimeof firststudydruginfusion,comparedusing a Van Elteren test. Secondary outcomes included opioid use and HRQL. Of 208 children enrolled, 204 received the study drug (101 magnesium, 103 placebo). Between-group demographics and prerandomization treatment were similar. The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours formagnesiumvs 47.0 (24.0-99.0) hours for placebo (P =.24). Magnesium patients received 1.46 mg/kg morphine equivalents vs 1.28 mg/kg for placebo (P =.12). Changes in HRQL before discharge and 1 week after discharge were similar (P >.05 for all comparisons). The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis.",
author = "{for the Pediatric Emergency Care Applied Research Network (PECARN)} and Brousseau, {David C.} and Scott, {J. Paul} and Oluwakemi Badaki-Makun and Darbari, {Deepika S.} and Chumpitazi, {Corrie E.} and Airewele, {Gladstone E.} and Ellison, {Angela M.} and Kim Smith-Whitley and Prashant Mahajan and Sarnaik, {Sharada A.} and Casper, {T. Charles} and Cook, {Lawrence J.} and Dean, {J. Michael} and Julie Leonard and Hulbert, {Monica L.} and Powell, {Elizabeth C.} and Liem, {Robert I.} and Robert Hickey and Lakshmanan Krishnamurti and Hillery, {Cheryl A.} and Mark Nimmer and Panepinto, {Julie A.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1182/blood-2015-05-647107",
language = "English (US)",
volume = "126",
pages = "1651--1657",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

for the Pediatric Emergency Care Applied Research Network (PECARN) 2015, 'A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children', Blood, vol. 126, no. 14, pp. 1651-1657. https://doi.org/10.1182/blood-2015-05-647107

A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. / for the Pediatric Emergency Care Applied Research Network (PECARN).

In: Blood, Vol. 126, No. 14, 01.10.2015, p. 1651-1657.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children

AU - for the Pediatric Emergency Care Applied Research Network (PECARN)

AU - Brousseau, David C.

AU - Scott, J. Paul

AU - Badaki-Makun, Oluwakemi

AU - Darbari, Deepika S.

AU - Chumpitazi, Corrie E.

AU - Airewele, Gladstone E.

AU - Ellison, Angela M.

AU - Smith-Whitley, Kim

AU - Mahajan, Prashant

AU - Sarnaik, Sharada A.

AU - Casper, T. Charles

AU - Cook, Lawrence J.

AU - Dean, J. Michael

AU - Leonard, Julie

AU - Hulbert, Monica L.

AU - Powell, Elizabeth C.

AU - Liem, Robert I.

AU - Hickey, Robert

AU - Krishnamurti, Lakshmanan

AU - Hillery, Cheryl A.

AU - Nimmer, Mark

AU - Panepinto, Julie A.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises.Wehypothesized that intravenousmagnesiumwould shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sb0 thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcomewaslengthof stay inhours fromthetimeof firststudydruginfusion,comparedusing a Van Elteren test. Secondary outcomes included opioid use and HRQL. Of 208 children enrolled, 204 received the study drug (101 magnesium, 103 placebo). Between-group demographics and prerandomization treatment were similar. The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours formagnesiumvs 47.0 (24.0-99.0) hours for placebo (P =.24). Magnesium patients received 1.46 mg/kg morphine equivalents vs 1.28 mg/kg for placebo (P =.12). Changes in HRQL before discharge and 1 week after discharge were similar (P >.05 for all comparisons). The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis.

AB - Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises.Wehypothesized that intravenousmagnesiumwould shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sb0 thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcomewaslengthof stay inhours fromthetimeof firststudydruginfusion,comparedusing a Van Elteren test. Secondary outcomes included opioid use and HRQL. Of 208 children enrolled, 204 received the study drug (101 magnesium, 103 placebo). Between-group demographics and prerandomization treatment were similar. The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours formagnesiumvs 47.0 (24.0-99.0) hours for placebo (P =.24). Magnesium patients received 1.46 mg/kg morphine equivalents vs 1.28 mg/kg for placebo (P =.12). Changes in HRQL before discharge and 1 week after discharge were similar (P >.05 for all comparisons). The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis.

UR - http://www.scopus.com/inward/record.url?scp=84947996077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947996077&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-05-647107

DO - 10.1182/blood-2015-05-647107

M3 - Article

C2 - 26232172

AN - SCOPUS:84947996077

VL - 126

SP - 1651

EP - 1657

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -